These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
495 related articles for article (PubMed ID: 30296896)
1. Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. Gould TD; Zarate CA; Thompson SM Annu Rev Pharmacol Toxicol; 2019 Jan; 59():213-236. PubMed ID: 30296896 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of ketamine and its metabolites as antidepressants. Hess EM; Riggs LM; Michaelides M; Gould TD Biochem Pharmacol; 2022 Mar; 197():114892. PubMed ID: 34968492 [TBL] [Abstract][Full Text] [Related]
3. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. Aleksandrova LR; Phillips AG; Wang YT J Psychiatry Neurosci; 2017 Jun; 42(4):222-229. PubMed ID: 28234212 [TBL] [Abstract][Full Text] [Related]
4. Ketamine: A tale of two enantiomers. Jelen LA; Young AH; Stone JM J Psychopharmacol; 2021 Feb; 35(2):109-123. PubMed ID: 33155503 [TBL] [Abstract][Full Text] [Related]
5. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038 [TBL] [Abstract][Full Text] [Related]
6. Glutamatergic Modulators for Major Depression from Theory to Clinical Use. McIntyre RS; Jain R CNS Drugs; 2024 Nov; 38(11):869-890. PubMed ID: 39150594 [TBL] [Abstract][Full Text] [Related]
8. The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways. Ren L Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110910. PubMed ID: 38061484 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants]. Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380 [TBL] [Abstract][Full Text] [Related]
14. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Krystal JH; Kaye AP; Jefferson S; Girgenti MJ; Wilkinson ST; Sanacora G; Esterlis I Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2305772120. PubMed ID: 38011560 [TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Hashimoto K Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141 [TBL] [Abstract][Full Text] [Related]
16. NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research. Lv S; Yao K; Zhang Y; Zhu S Neuropharmacology; 2023 Mar; 225():109378. PubMed ID: 36539011 [TBL] [Abstract][Full Text] [Related]
17. Is the antidepressant effect of ketamine separate from its psychotomimetic effect? A review of rodent models. Acero-Castillo MC; Correia MBM; Caixeta FV; Motta V; Barros M; Maior RS Neuropharmacology; 2024 Nov; 258():110088. PubMed ID: 39032814 [TBL] [Abstract][Full Text] [Related]
18. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Hashimoto K Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725 [TBL] [Abstract][Full Text] [Related]
19. mGlu2/3 receptor as a novel target for rapid acting antidepressants. Chaki S Adv Pharmacol; 2020; 89():289-309. PubMed ID: 32616210 [TBL] [Abstract][Full Text] [Related]